After Capital-Markets Day Flop, Novo Strikes Licensing Deal That Sends a Swedish Company's Stock Soaring

Dow Jones09-25 17:11

Novo Nordisk struck a licensing deal with a Swedish company worth over $1 billion.

Just days after a capital-markets day left investors wondering what's next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.

The deal announced on Thursday give Novo a global exclusive license to a drug-delivery technology platform from Sweden's Nanexa for certain therapeutic peptide drugs in medical conditions including obesity, type 2 diabetes and other cardiometabolic diseases.

Novo is the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, but investors are concerned that its next-generation products are lacking.

Nanexa is eligible to receive upfront consideration and potential milestone payments totaling up to EUR1.17 billion ($1.3 billion), including EUR615 million in upfront payment and development and regulatory milestones. In addition, the agreement provides for low single-digit royalties on future product sales.

The news sent the Swedish company (SE:NANEXA) , which has a separate pact with Moderna, up 127% in Stockholm.

Novo Nordisk stock (NVO) (DK:NOVO.B) edged up 0.2% in Copenhagen. The stock has lost 22% this year and has floundered since 2024.

-Steve Goldstein

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2670494824?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-25 17:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2670494824","market":"us","top_or_hot":-1,"title":"After Capital-Markets Day Flop, Novo Strikes Licensing Deal That Sends a Swedish Company's Stock Soaring","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Novo Nordisk struck a licensing deal with a Swedish company worth over $1 billion. \n</p>\n<p>\n     Just days after a capital-markets day left investors wondering what's next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion. \n</p>\n<p>\n     The deal announced on Thursday give Novo a global exclusive license to a drug-delivery technology platform from Sweden's Nanexa for certain therapeutic peptide drugs in medical conditions including obesity, type 2 diabetes and other cardiometabolic diseases. \n</p>\n<p>\n     Novo is the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, but investors are concerned that its next-generation products are lacking. \n</p>\n<p>\n     Nanexa is eligible to receive upfront consideration and potential milestone payments totaling up to EUR1.17 billion ($1.3 billion), including EUR615 million in upfront payment and development and regulatory milestones. In addition, the agreement provides for low single-digit royalties on future product sales. \n</p>\n<p>\n     The news sent the Swedish company (SE:NANEXA) , which has a separate pact with Moderna, up 127% in Stockholm. \n</p>\n<p>\n     Novo Nordisk stock (NVO) (DK:NOVO.B) edged up 0.2% in Copenhagen. The stock has lost 22% this year and has floundered since 2024. \n</p>\n<p>\n     -Steve Goldstein \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Capital-Markets Day Flop, Novo Strikes Licensing Deal That Sends a Swedish Company's Stock Soaring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Capital-Markets Day Flop, Novo Strikes Licensing Deal That Sends a Swedish Company's Stock Soaring\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-25 17:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Novo Nordisk struck a licensing deal with a Swedish company worth over $1 billion. \n</p>\n<p>\n     Just days after a capital-markets day left investors wondering what's next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion. \n</p>\n<p>\n     The deal announced on Thursday give Novo a global exclusive license to a drug-delivery technology platform from Sweden's Nanexa for certain therapeutic peptide drugs in medical conditions including obesity, type 2 diabetes and other cardiometabolic diseases. \n</p>\n<p>\n     Novo is the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, but investors are concerned that its next-generation products are lacking. \n</p>\n<p>\n     Nanexa is eligible to receive upfront consideration and potential milestone payments totaling up to EUR1.17 billion ($1.3 billion), including EUR615 million in upfront payment and development and regulatory milestones. In addition, the agreement provides for low single-digit royalties on future product sales. \n</p>\n<p>\n     The news sent the Swedish company (SE:NANEXA) , which has a separate pact with Moderna, up 127% in Stockholm. \n</p>\n<p>\n     Novo Nordisk stock (NVO) (DK:NOVO.B) edged up 0.2% in Copenhagen. The stock has lost 22% this year and has floundered since 2024. \n</p>\n<p>\n     -Steve Goldstein \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2670494824","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2670494824","pubTimestamp":1790327460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk struck a licensing deal with a Swedish company worth over $1 billion.Just days after a capital-markets day left investors wondering what's next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.The deal announced on Thursday give Novo a global exclusive license to a drug-delivery technology platform from Sweden's Nanexa for certain therapeutic peptide drugs in medical conditions including obesity, type 2 diabetes and other cardiometabolic diseases.Novo is the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, but investors are concerned that its next-generation products are lacking.Nanexa is eligible to receive upfront consideration and potential milestone payments totaling up to EUR1.17 billion , including EUR615 million in upfront payment and development and regulatory milestones. In addition, the agreement provides for low single-digit royalties on future product sales.The news sent the Swedish company  , wh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","OZEM":"Roundhill GLP-1 & Weight Loss ETF","BK4599":"减肥药","NVOX":"2倍做多NVO ETF-Defiance","PPH":"VanEck Pharmaceutical ETF","NVO":"诺和诺德","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NRNVF":"NORDIC NANOVECTOR AS","BK4007":"制药","NVOC":"Corgi NVO 2x Daily ETF","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"资本市场日崩盘后，Novo达成许可协议，导致一家瑞典公司股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OZEM":0.6,"NRNVF":1.87,"NVOX":0.6,"NVOC":0.6,"PPH":0.6,"NVO":1.95,"THNR":0.6,"NVOH":0.6},"content_text":"Novo Nordisk struck a licensing deal with a Swedish company worth over $1 billion. \n\n\n     Just days after a capital-markets day left investors wondering what's next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion. \n\n\n     The deal announced on Thursday give Novo a global exclusive license to a drug-delivery technology platform from Sweden's Nanexa for certain therapeutic peptide drugs in medical conditions including obesity, type 2 diabetes and other cardiometabolic diseases. \n\n\n     Novo is the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, but investors are concerned that its next-generation products are lacking. \n\n\n     Nanexa is eligible to receive upfront consideration and potential milestone payments totaling up to EUR1.17 billion ($1.3 billion), including EUR615 million in upfront payment and development and regulatory milestones. In addition, the agreement provides for low single-digit royalties on future product sales. \n\n\n     The news sent the Swedish company (SE:NANEXA) , which has a separate pact with Moderna, up 127% in Stockholm. \n\n\n     Novo Nordisk stock (NVO) (DK:NOVO.B) edged up 0.2% in Copenhagen. The stock has lost 22% this year and has floundered since 2024. \n\n\n     -Steve Goldstein","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2670494824","isCrawlerRequest":true}